Raffaele Colombo/LinkedIn
Jan 13, 2025, 13:44
Raffaele Colombo: Another EGFR and HER3 bispecific ADC will start clinical development in China
Rafaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared a post on X:
“And another EGFRxHER3 bispecific ADC will start clinical development in China!
JS212, developed by Shangai Junshi Biosciences.”
Earlier this week Raffaele Colombo shared on X:
“Avenzo Therapeutics licensed DualityBio’s preclinical bispecific ADC DB-1418 (= AVZO-1418)
bispecific EGFRxHER3, 1+1 format
P1021 payload (topo1i), DAR=6
Phase 1 expected to start this year.”
Raffaele Colombo, a leading figure in the pharmaceutical industry is the Associate Director of Medicinal Chemistry at Zymeworks Inc.. His leadership and scientific acumen drive the discovery and optimization of novel drug candidates and advance the treatment landscape for various diseases.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 1, 2025, 12:16
Apr 1, 2025, 12:13
Apr 1, 2025, 12:07
Apr 1, 2025, 11:53
Apr 1, 2025, 11:51
Apr 1, 2025, 11:42